Modern inhibitor of sodium-glucose cotransporter type 2 – ertugliflozin

Abstract

Diabetes mellitus, a well-known risk of cardiovascular disease (CVD), in patients with type 2 diabetes mellitus (DM2) Hyperglycemia has been found to be an increased risk of coronary heart disease and mortality. In real clinical practice, physicians are faced with the problem of choice when prescribing new hypoglycemic drugs in patients with type 2 diabetes and high cardiovascular risk. Modern possibilities and approaches to the treatment of DM2 have contributed to the creation of a promising class of hypoglycemic drugs that block renal glucose reabsorption - inhibitors of the sodium-glucose cotransporter type 2 (iSGLT-2). The unique mechanism of SGLT2 inhibition not only improves glycemic control, but also has cardio- and nephroprotective effects in patients with DM2 and at high cardiovascular risk. According to current recommendations, when choosing the tactics of treating patients with DM2 and the presence of risk factors for cardiovascular diseases or confirmed atherosclerotic cardiovascular diseases, preference is given to GLP-1 and/or iSGLT-2 receptor agonists in combination with the first-line drug, metformin. This article presents the main results of the efficacy and safety of ertugliflozin in a number of clinical studies and its beneficial effect not only on glycemic control, but also on cardio- and nephroprotective effects. The article also reflects the key results of an extensive program of randomized clinical trials VERTIS (acronym for eValuation of ERTugliflozinefficacy and Safety; evaluation of the efficacy and safety of ertugliflozin): including patients with type 2 diabetes and established atherosclerotic cardiovascular disease (VERTIS CV), with type 2 diabetes and CKD 3rd stage (VERTIS RENAL), as well as VERTIS MONO, VERTIS MET, VERTIS SITA, VERTIS SU and VERTIS FACTORIAL.